Q4 Earnings Forecast for Altimmune Issued By HC Wainwright

Altimmune, Inc. (NASDAQ:ALT) – Equities researchers at HC Wainwright issued their Q4 2027 earnings per share (EPS) estimates for shares of Altimmune in a report released on Monday, March 16th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%.

A number of other analysts have also recently commented on ALT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Barclays started coverage on shares of Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 target price on the stock. Wall Street Zen cut shares of Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Thursday, March 5th. Finally, B. Riley Financial reduced their price objective on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Altimmune has an average rating of “Hold” and a consensus price target of $19.20.

Altimmune Stock Down 2.5%

Shares of NASDAQ:ALT opened at $3.53 on Tuesday. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.15. Altimmune has a 52-week low of $2.90 and a 52-week high of $7.73. The stock’s fifty day simple moving average is $4.48 and its 200-day simple moving average is $4.29. The company has a market capitalization of $459.15 million, a P/E ratio of -3.50 and a beta of 0.13.

Insider Activity at Altimmune

In related news, Director John Gill bought 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the purchase, the director directly owned 12,500 shares in the company, valued at $51,250. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jerome Benedict Durso bought 20,000 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were bought at an average price of $3.54 per share, with a total value of $70,800.00. Following the completion of the purchase, the chief executive officer owned 32,500 shares in the company, valued at approximately $115,050. The trade was a 160.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have purchased 55,527 shares of company stock valued at $213,778. 4.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Two Sigma Investments LP lifted its stake in shares of Altimmune by 356.6% in the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after buying an additional 1,559,562 shares during the period. State Street Corp grew its position in Altimmune by 42.2% during the fourth quarter. State Street Corp now owns 5,119,703 shares of the company’s stock worth $18,482,000 after buying an additional 1,518,448 shares in the last quarter. Vanguard Group Inc. increased its stake in Altimmune by 23.3% during the third quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock valued at $24,029,000 after acquiring an additional 1,206,514 shares during the period. Nuveen LLC increased its stake in Altimmune by 514.9% during the fourth quarter. Nuveen LLC now owns 1,244,211 shares of the company’s stock valued at $4,492,000 after acquiring an additional 1,041,856 shares during the period. Finally, Marshall Wace LLP acquired a new position in Altimmune in the 4th quarter valued at approximately $3,331,000. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.